|Bid||8.55 x 3200|
|Ask||8.65 x 1100|
|Day's Range||8.50 - 8.80|
|52 Week Range||4.80 - 10.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Minerva Neurosciences Inc. shares rose 5.4% in premarket trade on Thursday after results from a phase 2b trial for a schizophrenia drug were published in the peer-reviewed The Journal of Clinical Psychiatry. ...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 32 cents. Minerva Neurosciences shares have risen 14 percent since the beginning of the year. The stock has fallen nearly ...
The Waltham, Massachusetts-based company said it had net income of less than 1 cent on a per-share basis. Losses, adjusted for pretax gains, were 24 cents per share. For the year, the company reported ...
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
Minerva Neurosciences Inc (NASDAQ:NERV), a pharmaceuticals, biotechnology and life sciences company based in United States, Check out our latest analysis for Minerva Neurosciences What’s the opportunity in NERV? Great newsRead More...
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
The Emeryville, Calif.-based firm secures FDA approval for Gocovri as a treatment for dyskinesia in Parkinson's disease patients.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 27 cents. Minerva Neurosciences shares have fallen 43 percent since the beginning of the year. The stock has dropped ...
Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.